Details

Last Funding Type

Series B

Last Funding Money Raised

$6.25M

Industries

Biotechnology,Genetics,Therapeutics

Founded date

Jan 1, 2005

Number Of Employee

1 - 10

Operating Status

Active

NanoCor Therapeutics is a biotechnology company founded to create a viable intracellular genetic protein therapy for the treatment of Chronic Heart Failure (CHF). The company was spun off from Asklêpios BioPharmaceutical, Inc. in November 2005.

NanoCor’s initial focus is the commercial development of a non-invasive treatment for CHF. NanoCor’s therapeutic is comprised of the delivery of a proprietary gene developed at the Massachusetts General Hospital and the University of Cincinnati. The gene will be delivered with AskBio’s proprietary Biological NanoParticle (BNP™) and the Self-Complementary Vector technologies, which are derived from human adeno-associated virus vectors (rAAV).